Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NeuroPace (NPCE) Capital Expenditures (2020 - 2025)

NeuroPace has reported Capital Expenditures over the past 6 years, most recently at $331000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at $331000.0 for Q4 2025, up 748.72% from a year ago — trailing twelve months through Dec 2025 was $332000.0 (up 8.5% YoY), and the annual figure for FY2025 was $332000.0, up 8.5%.
  • Capital Expenditures for Q4 2025 was $331000.0 at NeuroPace, up from -$204000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for NPCE hit a ceiling of $439000.0 in Q2 2022 and a floor of -$466000.0 in Q3 2022.
  • Median Capital Expenditures over the past 5 years was $77500.0 (2024), compared with a mean of $67500.0.
  • Biggest five-year swings in Capital Expenditures: plummeted 361.8% in 2022 and later surged 1011.11% in 2024.
  • NeuroPace's Capital Expenditures stood at $154000.0 in 2021, then dropped by 22.08% to $120000.0 in 2022, then plummeted by 160.0% to -$72000.0 in 2023, then skyrocketed by 154.17% to $39000.0 in 2024, then skyrocketed by 748.72% to $331000.0 in 2025.
  • The last three reported values for Capital Expenditures were $331000.0 (Q4 2025), -$204000.0 (Q3 2025), and $168000.0 (Q2 2025) per Business Quant data.